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Abstract
© 2018, Macmillan Publishers Limited, part of Springer Nature. Neural precursor cell expressed,
developmentally downregulated 9 (NEDD9) supports oncogenic signaling in a number of solid
and hematologic tumors. Little is known about the role of NEDD9 in ovarian carcinoma (OC), but
available data suggest elevated mRNA and protein expression in advanced stage high-grade
cancers. We used a transgenic MISIIR-TAg mouse OC model combined with genetic ablation of
Nedd9  to  investigate  its  action  in  the  development  and  progression  of  OC.  A  Nedd9−/−
genotype delayed tumor growth rate, reduced incidence of ascites, and reduced expression and
activation  of  signaling  proteins  including  SRC,  STAT3,  E-cadherin,  and  AURKA.  Cell  lines
established  from  MISIIR-TAg;Nedd9−/−  and  MISIIR-TAg;Nedd9+/+  mice  exhibited  altered
migration and invasion. Growth of these cells in a syngeneic allograft model indicated that
systemic Nedd9 loss in the microenvironment had little impact on tumor allograft growth, but in
a Nedd9 wild-type background Nedd9−/− allografts  exhibited significantly  reduced growth,
dissemination,  and oncogenic signaling compared to Nedd9+/+ allografts.  Gene expression
analysis  revealed  that  Nedd9+/+  tumors  exhibited  more  mesenchymal  “stem-like”
transcriptional program, including increased expression of Aldh1a1 and Aldh1a2. Conversely,
loss of Nedd9 resulted in increased expression of differentiation genes, including fallopian tube
markers Foxj1, Ovgp1, and Pax8. Collectively, these data suggest that tumor cell-intrinsic Nedd9
expression promotes OC development and progression by broad induction of oncogenic protein
signaling and stem/mesenchymal gene expression.
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